PLx Pharma Winddown Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
PLx Pharma Winddown has been growing earnings at an average annual rate of 54.6%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually. Revenues have been declining at an average rate of 31.3% per year.
Anahtar bilgiler
54.6%
Kazanç büyüme oranı
68.0%
EPS büyüme oranı
Pharmaceuticals Sektör Büyümesi | 6.0% |
Gelir büyüme oranı | -31.3% |
Özkaynak getirisi | -104.7% |
Net Marj | -606.9% |
Son Kazanç Güncellemesi | 30 Sep 2022 |
Yakın geçmiş performans güncellemeleri
Recent updates
PLx Pharma Non-GAAP EPS of -$0.52 misses by $0.02, revenue of $0.48M
Aug 12Is PLx Pharma (NASDAQ:PLXP) In A Good Position To Deliver On Growth Plans?
May 10Most Shareholders Will Probably Find That The CEO Compensation For PLx Pharma Inc. (NASDAQ:PLXP) Is Reasonable
Nov 03We're Interested To See How PLx Pharma (NASDAQ:PLXP) Uses Its Cash Hoard To Grow
Sep 23PLx Pharma: First Commercial Launch Makes It Attractive
Sep 17PLx Pharma (NASDAQ:PLXP) Is In A Strong Position To Grow Its Business
Jun 15Have Insiders Been Buying PLx Pharma Inc. (NASDAQ:PLXP) Shares?
Mar 05PLx Pharma EPS misses by $0.10
Nov 16Gelir ve Gider Dağılımı
PLx Pharma Winddown nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Sep 22 | 5 | -28 | 62 | 3 |
30 Jun 22 | 11 | -41 | 64 | 3 |
31 Mar 22 | 10 | -48 | 56 | 4 |
31 Dec 21 | 8 | -49 | 40 | 4 |
30 Sep 21 | 7 | -61 | 22 | 5 |
30 Jun 21 | 0 | -43 | 13 | 4 |
31 Mar 21 | 0 | -30 | 9 | 5 |
31 Dec 20 | 0 | -17 | 9 | 4 |
30 Sep 20 | 0 | -11 | 10 | 4 |
30 Jun 20 | 0 | -6 | 10 | 4 |
31 Mar 20 | 0 | -10 | 10 | 4 |
31 Dec 19 | 1 | -34 | 10 | 5 |
30 Sep 19 | 1 | -29 | 9 | 5 |
30 Jun 19 | 1 | -34 | 8 | 5 |
31 Mar 19 | 1 | -28 | 8 | 4 |
31 Dec 18 | 1 | 1 | 8 | 4 |
30 Sep 18 | 1 | -10 | 8 | 5 |
30 Jun 18 | 1 | -10 | 9 | 5 |
31 Mar 18 | 1 | -9 | 11 | 5 |
31 Dec 17 | 1 | -15 | 10 | 4 |
30 Sep 17 | 0 | -9 | 10 | 2 |
30 Jun 17 | 0 | -6 | 8 | 1 |
31 Mar 17 | 0 | -5 | 5 | 0 |
31 Dec 16 | 0 | -5 | 5 | 0 |
30 Sep 16 | 0 | -4 | 4 | 0 |
30 Jun 16 | 0 | -5 | 3 | 0 |
31 Mar 16 | 0 | -4 | 2 | 0 |
31 Dec 15 | 0 | -4 | 2 | 0 |
30 Sep 15 | 0 | -4 | 2 | 1 |
30 Jun 15 | 0 | -3 | 2 | 1 |
31 Mar 15 | 0 | -4 | 2 | 2 |
31 Dec 14 | 0 | -5 | 2 | 3 |
31 Dec 13 | 1 | -9 | 4 | 6 |
Kaliteli Kazançlar: PLXP.Q is currently unprofitable.
Büyüyen Kar Marjı: PLXP.Q is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: Insufficient data to determine if PLXP.Q's year-on-year earnings growth rate was positive over the past 5 years.
Büyüme Hızlandırma: Unable to compare PLXP.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: PLXP.Q is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-17.3%).
Özkaynak Getirisi
Yüksek ROE: PLXP.Q has a negative Return on Equity (-104.74%), as it is currently unprofitable.